Oculis (NASDAQ:OCS) Shares Up 7% – What’s Next?

Shares of Oculis Holding AG (NASDAQ:OCS) shot up 7% during mid-day trading on Thursday . The company traded as high as $30.25 and last traded at $29.8670. 372,065 shares traded hands during trading, an increase of 6% from the average session volume of 349,370 shares. The stock had previously closed at $27.91.

Analyst Ratings Changes

A number of research firms have issued reports on OCS. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a report on Tuesday, April 21st. HC Wainwright increased their target price on Oculis from $44.00 to $47.00 and gave the stock a “buy” rating in a report on Tuesday, May 12th. Guggenheim began coverage on Oculis in a report on Wednesday. They set a “buy” rating and a $75.00 target price for the company. Stifel Nicolaus increased their target price on Oculis from $40.00 to $50.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Finally, Wall Street Zen cut Oculis from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Oculis currently has a consensus rating of “Moderate Buy” and an average target price of $49.38.

Oculis Stock Performance

The stock’s 50 day moving average price is $27.39 and its 200 day moving average price is $24.74. The company has a current ratio of 5.18, a quick ratio of 5.18 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $1.79 billion, a price-to-earnings ratio of -14.49 and a beta of 0.38.

Oculis (NASDAQ:OCS) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.14). Oculis had a negative return on equity of 56.78% and a negative net margin of 8,460.67%.The business had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.25 million. Analysts expect that Oculis Holding AG will post -2.18 earnings per share for the current year.

Institutional Investors Weigh In On Oculis

Several hedge funds have recently bought and sold shares of the company. Bank of America Corp DE lifted its stake in Oculis by 9.1% in the 1st quarter. Bank of America Corp DE now owns 69,764 shares of the company’s stock valued at $1,855,000 after purchasing an additional 5,813 shares during the last quarter. Himension Capital Singapore PTE. LTD. acquired a new stake in Oculis in the 1st quarter valued at about $503,000. Koshinski Asset Management Inc. acquired a new stake in Oculis in the 1st quarter valued at about $238,000. Y Intercept Hong Kong Ltd acquired a new stake in Oculis in the 1st quarter valued at about $776,000. Finally, Perceptive Advisors LLC acquired a new stake in Oculis in the 4th quarter valued at about $9,862,000. 22.30% of the stock is currently owned by institutional investors and hedge funds.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.